Dermapharm Holding - EU Taxonomy Data: Eligible & Aligned Revenues, CAPEX & OPEX

Dermapharm Holding's EU Taxonomy Data Preview

In 2024, Dermapharm Holding was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.

The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.

Dermapharm Holding has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Dermapharm Holding are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.

turnoveropexcapex

Metric (tonnes)	2025	2024	2023	2022 - 2017
Total Taxonomy Aligned A1 Turnover Portion of total company turnover generated from economic activities that are eligible under the EU Taxonomy and meet all alignment requirements, including substantial contribution, Do No Significant Harm (DNSH), and minimum safeguards.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Data available for purchase 0000000
Total Taxonomy Eligible A Turnover Total turnover of the company associated with activities considered eligible under the EU Taxonomy, regardless of whether they meet alignment criteria.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000
Total Taxonomy Non-Eligible B Turnover Total turnover of the company associated with activities that are not listed as eligible under the EU Taxonomy.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000

Metric (tonnes)	2025	2024	2023	2022 - 2017
Total Taxonomy Aligned A1 Opex Portion of total company OPEX generated from economic activities that are eligible under the EU Taxonomy and meet all alignment requirements, including substantial contribution, Do No Significant Harm (DNSH), and minimum safeguards.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Data available for purchase 0000000
Total Taxonomy Eligible A Opex Total OPEX of the company associated with activities considered eligible under the EU Taxonomy, regardless of whether they meet alignment criteria.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000
Total Taxonomy Non-Eligible B Opex Total OPEX of the company associated with activities that are not listed as eligible under the EU Taxonomy.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000

Metric (tonnes)	2025	2024	2023	2022 - 2017
Total Taxonomy Aligned A1 Capex Portion of total company CAPEX generated from economic activities that are eligible under the EU Taxonomy and meet all alignment requirements, including substantial contribution, Do No Significant Harm (DNSH), and minimum safeguards.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Data available for purchase 0000000
Total Taxonomy Eligible A Capex Total CAPEX of the company associated with activities considered eligible under the EU Taxonomy, regardless of whether they meet alignment criteria.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000
Total Taxonomy Non-Eligible B Capex Total CAPEX of the company associated with activities that are not listed as eligible under the EU Taxonomy.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000
Activity Level Taxonomy Aligned A1 Capex (1 activity)
4.1 CCM/CCA - Electricity generation using solar photovoltaic technology 4.1 CCM/CCA - Electricity generation using solar photovoltaic technology	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Data available for purchase 0000000

Verified Sources Behind Dermapharm Holding’s EU Taxonomy Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Dermapharm Holding’s data sources below and access millions more through our Disclosure Search.

a. Dermapharm Holding's Non-financial report 2024

b. Dermapharm Holding's CSR Report 2023

c. Dermapharm Holding's CSR Report 2022

Insights into Dermapharm Holding's Revenues from Sustainable Activities

In 2024, Dermapharm Holding reported EU Taxonomy-eligible revenues of EUR 608.20 million, representing 51.5% of its total turnover. Of this amount, EUR 0 of Dermapharm Holding's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).^a

Insights into Dermapharm Holding's CAPEX from Sustainable Activities

In 2024, Dermapharm Holding reported EU Taxonomy-eligible CAPEX of EUR 27.30 million,representing 61.2% of its total CAPEX. Of this amount, EUR 0 of Dermapharm Holding's CAPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).^a

Dermapharm Holding's Taxonomy-Eligible Capex Over Time

Total Taxonomy Aligned A1 Capex
Total Taxonomy Eligible but Not Aligned A2 Capex

Have Dermapharm Holding's increased its investment in sustainable activities over time?

Since 2022, Dermapharm Holding's taxonomy-aligned capital expenditure (CAPEX)decreased by 100%,indicating a long-term decline in green capital deployment, potentially signaling shifting priorities or reduced focus on sustainability-linked investments.^{a, c}

Insights into Dermapharm Holding's OPEX from Sustainable Activities

In 2024, Dermapharm Holding reported EU Taxonomy-eligible OPEX of EUR 23.50 million,representing 70.1% of its total operating expenses (OPEX). Of this amount, EUR 0 of Dermapharm Holding's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).^a

Dermapharm Holding's Taxonomy-Eligible Opex Over Time

Total Taxonomy Aligned A1 Opex
Total Taxonomy Eligible but Not Aligned A2 Opex

Have Dermapharm Holding's increased its spending in sustainable activities over time?

Since 2022, Dermapharm Holding's taxonomy-aligned operating expenditure (OPEX)decreased by 100%,indicating a long-term decline in sustainability-related operational spending, which may reflect shifting priorities or reduced emphasis on green initiatives.^{a, c}

Welcome Back to Tracenable

Sign in to your account

Dermapharm Holding SE

Dermapharm Holding's EU Taxonomy Data Preview

Verified Sources Behind Dermapharm Holding’s EU Taxonomy Data

Insights into Dermapharm Holding's Revenues from Sustainable Activities

Insights into Dermapharm Holding's CAPEX from Sustainable Activities

Dermapharm Holding's Taxonomy-Eligible Capex Over Time

Have Dermapharm Holding's increased its investment in sustainable activities over time?

Insights into Dermapharm Holding's OPEX from Sustainable Activities

Dermapharm Holding's Taxonomy-Eligible Opex Over Time

Have Dermapharm Holding's increased its spending in sustainable activities over time?

Explore Peer Companies

Evotec SE

Biotest AG

Mediclin AG

Nexus AG

Rhoen Klinikum AG

Eckert & Ziegler SE